Trial Profile

A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZT 002 (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions; First in man
Sponsors QL Biopharmaceutical

Most Recent Events

12 May 2023 Planned number of patients changed from 32 to 56.
12 May 2023 Planned End Date changed from 31 Aug 2023 to 14 Apr 2024.
12 May 2023 Planned primary completion date changed from 14 Feb 2023 to 14 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com